Stephen A. Adelstein is a Pulmonologist working in Camperdown, NSW, at 50 Missenden Rd. He looks after people with a wide range of breathing and lung conditions, especially when the problem is complex or doesn’t fit into a simple box.
In day to day practice, he helps patients who have long-term lung problems like pulmonary fibrosis and interstitial lung disease. These can come with ongoing breathlessness, a dry cough, and changes seen on scans. He also supports people dealing with inflammatory lung issues such as hypersensitivity pneumonitis, and at times conditions like acute interstitial pneumonia, where symptoms can develop quickly and need careful attention.
Some cases involve other body systems too, because lung issues can link with immune and inflammatory conditions. For example, he sees patients with conditions such as lupus and systemic sclerosis, where the lungs can be affected. He also works with people who have had pneumonia or other serious infections, and he helps sort out what’s going on so treatment is safer and more targeted.
Stephen also comes across rarer and harder diagnoses. These may include mesothelioma, and a range of blood or immune-related conditions where the lungs can be involved, such as hairy cell leukaemia and other histiocytic disorders. When someone has severe symptoms like these, the goal is to take a steady approach, ask the right questions, and make sure the plan matches the person’s overall health.
Over time, his experience in respiratory medicine means he’s used to working through tricky cases with care. He considers both the breathing side of things and the wider health picture. He works closely with other doctors and specialists, so patients get coordinated care rather than pieces that don’t quite connect.
Stephen has completed specialist medical training and hospital-based clinical work, building the skills needed for lung assessments, ongoing management, and follow-up. He keeps up with new evidence in lung health, including how treatment approaches change as research improves. At times, that can also mean looking at the role of new therapies and what might be available through appropriate clinical pathways, depending on the patient.
